A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)

Trial Profile

A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs Trafermin (Primary)
  • Indications Periodontitis
  • Focus Pharmacokinetics; Registrational
  • Sponsors Kaken Pharmaceutical
  • Most Recent Events

    • 01 Oct 2015 According to Kaken Pharmaceutical media release, the company submitted a new drug application (NDA) for Trafermin [KDB-1D] to the Ministry of Health, Labour and Welfare in Japan.
    • 17 Jun 2014 New trial record
    • 14 Jun 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top